Brief: CLS Expects To Achieve Positive Cash Flow From Q4 2026 To Q1 2028
April 28 (Reuters) - Clinical Laserthermia Systems AB CLSRb.ST: CLS STRENGTHENS ITS STRATEGIC PARTNERSHIP IN NEUROSURGERY AND AIMS TO BECOME MARKET LEADER IN NEURO LITT CLINICAL LASERTHERMIA SYSTEMS AB - UPDATING GUIDANCE FOR ACHIEVING POSITIVE CASH FLOW FROM Q4 2026 TO Q1 2028 Source text: ID:nWkr922tdq Further company coverage: [CLSRb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Clinical Laserthermia Systems AB
See all newsBrief: CLS Enters Research Agreement With U.S. National Cancer Institute
Sweden's CLS Q1 sales fall 72% after partner talks
Brief: Clinical Laserthermia Systems Q1 EBIT Sek 1.7 Mln
Brief: CLS Receives Order Worth SEK 23 Mln For Prism Business
Brief: CLS Expects To Achieve Positive Cash Flow From Q4 2026 To Q1 2028